Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
The Quick Take
SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W SINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a)...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Small businesses hit with Aus Post underpaid postage fees despite photographic evidence - Yahoo Finance Australia
Small businesses hit with Aus Post underpaid postage fees despite photographic evidence Yahoo Finance Australia
Business
GlycoNex Announces Japanese Regulatory Submission for Denosumab Biosimilar SPD8
Regulatory decision in Japan anticipated as early as the end of 2027, subject to PMDA review; GlycoNex continues to seek partners for markets outside Japan NEW…
Business
OceanFirst Financial director Nicos Katsoulis buys $178,277 in stock
Local
Yordenis Ugás announces his new profession in the United States: "Always a Cuban, decent and hard-working." - CiberCuba
Yordenis Ugás announces his new profession in the United States: "Always a Cuban, decent and hard-working." CiberCuba